Skip to main content

Nasdaq IPOs

Fall 2020 US IPO Preview: Tech Unicorns Leap Through the IPO Window

6 years 1 month ago
The US IPO market roared back to life this summer, and recent filings signal a very active fall. 2020 is now on track to surpass last year by deal count and proceeds, with the biggest IPO market by capital raised since 2014. The IPO window is wide open, as tech multiples near hi
Renaissance Capital

Oncology biotech Prelude Therapeutics files for a $100 million IPO

6 years 1 month ago
Prelude Therapeutics, a Phase 1 biotech developing small molecule therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's first clinical candidate, PRT543, is currently in a Phase 1 trial in select solid tum
Renaissance Capital

Pulmonary medical device maker Pulmonx refiles for an $86 million IPO

6 years 1 month ago
Pulmonx, which makes minimally invasive medical devices for emphysema, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company previously filed to raise $86 million in February 2020 but withdrew the following May after raising $66 millio
Renaissance Capital

Ocular disease biotech Graybug Vision files for an $86 million IPO

6 years 1 month ago
Graybug Vision, a Phase 2 biotech developing transformative medicines for ocular diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company's lead candidate, GB-102, is an intravitreal injection being developed as a&nbsp
Renaissance Capital

Fall 2020 US IPO Preview: Tech Unicorns Leap Through the IPO Window

6 years 1 month ago
The US IPO market roared back to life this summer, and recent filings signal a very active fall. 2020 is now on track to surpass last year by deal count and proceeds, with the biggest IPO market by capital raised since 2014. The IPO window is wide open, as tech multiples near hi
Renaissance Capital

Danish rare disease biotech Orphazyme files for a $115 million US IPO

6 years 1 month ago
Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company is currently listed on the Nasdaq Copenhagen under the symbol "ORPHA." Orph
Renaissance Capital
Checked
4 minutes 48 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed